 |
|
 |
Drug Discovery |
|
|
Gastrointestinal Drug Discoveries
Publication Date January 2008
Publisher Espicom
Product Type Report
Pages 148
ISBN Number 978-1-85822-311-7
Product Code ESP1058
|
|
|
Summary
This new strategic report from Espicom provides a comprehensive review of current and future treatments for major gastrointestinal therapy areas: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastro-oesophageal reflux disease (GORD). Over 145 pages
of product analysis and forecasts
Unique market share and 5-year sales forecasts for leading products & prospects
A comprehensive examination of major gastrointestinal therapy areas
Critical competitive evaluation and scoring of current and up and coming products.
|
Content
- Executive Summary
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Other Factors Affecting the Bottom line
- Conclusions
- Therapeutic Area Focus
- R&d Pipeline
- Cardiovascular
- Marketed Products
- Adenocard
- Adenoscan
- Cibenol
- Dorner
- Frandol
- Lipitor
- Micardis
- Milrila
- Nivadil
- Perdipine
- Solinase
- Vaprisol
- R&D Projects
- ASP1585
- Regadenoson
- Vernakalant
- YM150
- YM311
- YM758
- Growth Forecast
- Urology
- Marketed Products
- Harnal/Omnic/Flomax
- Vesicare
- R&D Projects
- Growth Forecast
- Inflammation & Immunology
- Marketed Products
- Atock/Foradil
- Celecox
- Intal
- Prograf
- R&D Projects
- AGI-1096
- Parecoxib
- Valdecoxib (YM974)
- Growth Forecast
- Gastrointestinal
- Marketed Products
- Colonel (HSR 237)
- Ganaton
- Gaster/Pepcid
- Nasea
- R&D Projects
- Growth Forecast
- Infectious Disease
- Marketed Products
- Aimmugen
- AmBisome
- Cefamezin
- Cefspan
- Cefzon/Omnicef
- Funguard/Mycamine
- Geninax
- Infergen/Advaferon
- R&D Projects
- Growth Forecast
- Central Nervous System
- Marketed Products
- R&D Projects
- Growth Forecast
- Dermatology
- Growth Forecast
- Metabolic
- Marketed Products
- R&D Projects
- Growth Forecast
- Bone Disorders
- Marketed Products
- InductOs (YM484; rhBMP-2, dibotermin alpha)
- R&D Projects
- Growth Forecast
- Oncology
- Marketed Products
- R&D Projects
- Growth Forecast
- Appendix 1 - Financial Performance
- Appendix 2 - Key Corporate Events
- Appendix 3 - Key Agreements
- Ajinomoto Co Inc
- American BioScience Inc (ABS)
- AtheroGenics Inc
- Biogen Idec
- Boehringer Ingelheim (BI)
- Cardiome Pharma Corp
- Carlsson Research AB
- Cephalon Inc
- CV Therapeutics Inc (CVT)
- Ferring Pharmaceuticals
- FibroGen Inc
- Gilead Sciences Inc
- GlaxoSmithKline
- Gloucester Pharmaceuticals Inc
- Icagen Inc
- Ilypsa Inc
- Immuno-Biological Laboratories
- Kirin Brewery
- Metabolex Inc
- MorphoSys AG
- Mundipharma International
- Nippon Kayaku Co Ltd
- Novartis
- Ono Pharmaceutical Co Ltd
- Pfizer
- Pharmagenesis Inc
- Regeneron Pharmaceuticals Inc
- sanofi-aventis
- Senju Pharmaceutical Co Ltd
- SymBio Pharmaceuticals Ltd
- Taiho Pharmaceuticals Co Ltd
- Taisho Toyama Pharmaceutical Co Ltd
- TAP Pharmaceutical Products Inc
- Tercica Inc
- Theravance Inc
- Wyeth
- XenoPort Inc
- Zeria Pharmaceutical Co Ltd
- Appendix 4 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
- Appendix 5 - Key Pharmaceutical
- Subsidiaries/Joint Ventures
- subsidiaries
- Joint Ventures
- Index
- Index of Tables
- Principal Operating Results
- Sales by Business Area
- Sales by Destination
- Sales by Origin
- Operating Income (Loss) by Geographic Area
- Total Assets by Geographical Area
- Employees by Geographic Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular Products, 2007
- Major Urology Products, 2007
- Major Inflammation & Immunology Products, 2007
- New Indications
- Major Gastrointestinal Products, 2007
- Major Infectious Disease Products, 2007
- Major Central Nervous System Products, 2007
- Major Dermatology Products, 2007
- Major Metabolic Products, 2007
- Major Oncology Products, 2007
- Index of Charts
- Sales by Business Area
- Sales by Destination
- Sales by Origin
- Operating Income (Loss) by Geographic Area
- Total Assets by Geographical Area
- Employees by Geographic Area, 2007
- Sales of Current Top Ten Products (2001A-2012E)
- Adenoscan Sales (2002A-2012E)
- Cibenol Sales (2005A-2012E)
- Dorner Sales (2002A-2012E)
- Astellas
- Frandol Sales (2002A-2012E)
- Lipitor Sales (2002A-2012E)
- Micardis Sales (2003A-2012E)
- Nivadil Sales (2002A-2012E)
- Perdipine Sales (2002A-2012E)
- Regadenoson Sales (2008E-2014E)
- Vernakalant Sales (2008E-2014E)
- Flomax/Harnal/Omnic Sales (2002A-2012E)
- Intal Sales (2002A-2012E)
- Prograf Sales (2002A-2012E)
- Gaster/Pepcid Sales (2002A-2012E)
- Nasea Sales (2002A-2012E)
- AmBisome Sales (2002A-2012E)
- Cefamezin Sales (2002A-2012E)
- Cefspan Sales (2002A-2012E)
- Cefzon Sales (2002A-2012E)
- Funguard Sales (2003A-2012E)
- Garenoxacin Sales (2008E-2014E)
- Telavancin Sales (2008E-2014E)
- Dogmatyl Sales (2002A-2012E)
- Luvox Sales (2002A-2012E)
- Myslee Sales (2002A-2012E)
- Seroquel Sales (2002A-2012E)
- Protopic Sales (2002A-2012E)
- Starsis Sales (2002A-2012E)
- Minodronate Sales (2008E-2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
|
|
